Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes
Diabetes Technology & Therapeutics · 2024-08 · 26 (8) · 514-525
DOI: 10.1089/dia.2023.0578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 08.08.2024. Verfasst von Gregory P Forlenza und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Infusion Systems, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
The Omnipod ® 5 Automated Insulin Delivery System was associated with favorable glycemic outcomes for people with type 1 diabetes (T1D) in two pivotal clinical trials. Real-world evidence is needed to explore effectiveness in nonstudy conditions.
Methods
A retrospective analysis of the United States Omnipod 5 System users (aged ≥2 years) with T1D and sufficient data (≥90 days of data; ≥75% of days with ≥220 continuous glucose monitor readings/day) available in Insulet Corporation's device and person-reported datasets as of July 2023 was performed. Target glucose setting usage (i.e., 110–150 mg/dL in 10 mg/dL increments) was summarized and glycemic outcomes were examined. Subgroup analyses of those using the lowest average glucose target (110 mg/dL) and stratification by baseline characteristics (e.g., age, prior therapy, health insurance coverage) were conducted.
Results
In total, 69,902 users were included. Multiple and higher glucose targets were more commonly used in younger age groups. Median percentage of time in range (TIR; 70–180 mg/dL) was 68.8%, 61.3%, and 53.6% for users with average glucose targets of 110, 120, and 130–150 mg/dL, respectively, with minimal time
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
- Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Translational Medical Sciences, University of Nottingham, School of Medicine, Royal Derby Hospital, Derby, United Kingdom.
- Insulet Corporation, Acton, Massachusetts, USA.
- Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Gregory P Forlenza, Daniel J DeSalvo, Trang T Ly, Jennifer L Sherr
Zitieren
APA
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., & Sherr, J. L. (2024). Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics, 26(8), 514-525. https://doi.org/10.1089/dia.2023.0578
Vancouver
Forlenza GP, DeSalvo DJ, Aleppo G, Wilmot EG, Berget C, Huyett LM, et al. Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2024;26(8):514-525. doi:10.1089/dia.2023.0578
BibTeX
@article{Forlenza2024,
author = {Forlenza, Gregory P and DeSalvo, Daniel J and Aleppo, Grazia and Wilmot, Emma G and Berget, Cari and Huyett, Lauren M and Hadjiyianni, Irene and Méndez, José J and Conroy, Lindsey R and Ly, Trang T and Sherr, Jennifer L},
title = {Real-World Evidence of Omnipod ® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {8},
pages = {514--525},
doi = {10.1089/dia.2023.0578}
}
EUVIMED